Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance

BACKGROUND: Interleukin-2 (IL-2) serves as a pioneer of immunotherapeutic agent in cancer treatment. However, there is a considerable proportion of patients who cannot benefit from this therapy due to the limited clinical responses and dose-limiting toxicities. Mounting evidence indicates that comme...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Linlin, Sheng, Jianyong, Chen, Guozhong, Zhu, Peng, Shi, Changping, Li, Bei, Park, Chaiwoo, Wang, Jingyi, Zhang, Bixiang, Liu, Zhi, Yang, Xiangliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542661/
https://www.ncbi.nlm.nih.gov/pubmed/33028692
http://dx.doi.org/10.1136/jitc-2020-000973

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542661/
https://www.ncbi.nlm.nih.gov/pubmed/33028692
http://dx.doi.org/10.1136/jitc-2020-000973

Ejemplares similares